|
|
|
06.10.26 - 06:30
|
Midday Takeaway: HSI Closes Midday at 24,228, Up 188 pts; HSTI Closes Midday at 4,220, Up 36 pts; J&T EXPRESS-W Up over 4%; WUXI BIO, GENSCRIPT BIO Hit New Highs (AAStocks)
|
|
|
At midday close, HSI rose 188 pts or 0.8% to 24,228. HSTI rose 36 pts or 0.9% to 4,220. HSCEI gained 66 pts or 0.8% to 8,118.Active Heavyweights:BABA (09988.HK) closed at $108.3, up 2.8%XIAOMI (01810.HK) closed at $24.32, up 1.8%TENCENT (00700.HK) closed at $427.8, up 1.1%PING AN (02318.HK) closed at $51.5, down 0.5%HSI & HSCEI ......
|
|
|
30.09.26 - 12:45
|
HKD1.4B Southbound Trading Net Inflow to TENCENT (AAStocks)
|
|
|
There was HKD1.4 billion, HKD178.8 million and HKD166.7 million Southbound Trading net inflow to TENCENT (00700.HK), WUXI BIO (02269.HK) and MINIMAX-W (00100.HK).There was HKD971.4 million, HKD145.9 million and HKD17.2 million Southbound Trading net outflow from SMIC (00981.HK), Z.AI (02513.HK) and AKESO (09926.HK).For Southboun......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.08.26 - 05:30
|
Research: Citi Raises WUXI BIO TP to HKD62, Rating Buy (AAStocks)
|
|
|
Citi released a report saying that WUXI BIO (02269.HK) management raised its 2026 revenue guidance to 20-23% YoY growth at constant exchange rates, compared with the previous forecast of 16-20%, or 15-18% YoY growth on a reported basis, compared with the previous forecast of 13-17%. The company maintained its guidance for a 20% ......
|
|
|
|
|
26.08.26 - 04:45
|
Research: Nomura Hikes WUXI BIO TP to HKD60.22; 1H Results Beat (AAStocks)
|
|
|
Both revenue and profit of WUXI BIO (02269.HK) beat the broker's and market expectations, Nomura said in a report. Revenue for 1H grew 18.4% YoY to RMB11.8 billion, slightly above the market and the broker's forecasts of RMB11.5 billion, while profit gained 4.3% YoY to RMB2.4 billion, higher than the market and the broke......
|
|
|
26.08.26 - 04:30
|
Research: M Stanley Raises WUXI BIO TP to HKD57, 1H Results Beat Expectations (AAStocks)
|
|
|
M Stanley issued a report stating that WUXI BIO (02269.HK)'s revenue and adjusted net profit for 1H26 were RMB11.8 billion and RMB3.306 billion respectively, representing YoY growth of 18.4% and 38.4%, and exceeding the broker's expectations by 3% and 20% respectively.The report noted that the company's management raised its ful......
|
|
|
|
|
25.08.26 - 15:06
|
WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds (SCMP)
|
|
|
WuXi Biologics, one of China's largest contract drug developers, posted a 4.3 per cent increase in profit attributable to shareholders in the first half of the year, as stronger demand and improved capacity utilisation lifted revenue and margins.
The Wuxi, Jiangsu-based company's net profit attributable to shareholders rose to 2.44 billion yuan (US$363 million) in the six months ended June, according to its filing to the Hong Kong stock exchange on Tuesday. Revenue increased 18.4 per cent to......
|
|
|
25.08.26 - 14:48
|
WuXi Biologics Reports Strong Profitable Growth in H1 2026 (PR Newswire)
|
|
|
Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD) IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite foreign exchange headwinds EBITDA grew 3.5% YoY and IFRS net profit rose 5.8% YoY; adjusted......
|
|
|
25.08.26 - 12:15
|
Results: WUXI BIO 1H26 NP Up 4.3% to RMB2.44B; Adj. NP Up 38.4% (AAStocks)
|
|
|
WUXI BIO (02269.HK) announced its interim results for the six months ended June 2026. Revenue lifted 18.4% YoY to RMB11.787 billion. Net profit gained 4.3% YoY to RMB2.44 billion, with EPS at RMB0.6. Adjusted net profit climbed 38.4% to RMB3.306 billion, while adjusted net profit margin improved from 24% to 28%. No dividend was ......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
